The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to \u00a316.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
Dr Duong Thi Hue Kien, a Post-doc Scientist at OUCRU, has shared her experience of finishing her PhD and kickstarting her career in science. She documents the highs and the lows, as well as how she was able to move forward in her career with support from the MORU\u2013OUCRU Discovery Research Academy.
The Kenya Medical Research Institute (KEMRI) has officially entered into a seven-year Memorandum of Understanding (MoU) with Wellcome, a UK-based charitable foundation, and the University of Oxford. The \u00a391 million agreement was signed at the Wellcome headquarters in London, marking a significant boost for medical research and training in Kenya.
Professor Susanna Dunachie and Dr Caesar Atuire of the Centre for Tropical Medicine and Global Health have been appointed as Co-Associate Directors of the Oxford Global Health initiative.
Cancer Research UK and partners have committed \u00a35.5 million in funding to form a world-leading research team, co-led by NDM\u2019s Professor Simon Leedham. The team\u2019s goal is to make personalised medicine a reality for people with bowel cancer.
The Jenner Institute, in partnership with the Coler Lab at Seattle Children\u2019s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.
Ranking 11th globally in antibiotic use, Vietnam faces a serious risk of drug resistance, and could be \u2018running out of treatment options due to antibiotic resistance\u2019.
Co-led by PSI Director Professor Sir Peter Horby, the RECOVERY trial was defined \"one of the most well-known studies supported by the NIHR with clear national and global impact.\u201d
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
In a recent study, researchers at the KEMRI Wellcome Trust Research Programme in Kenya have discovered that a low-dose of the yellow fever vaccine is as effective as the current standard dose.
Scientists have found another clue about how brain health is maintained and how this might be affected by ageing and Alzheimer\u2019s disease, according to a new paper.
Researchers have published the first paper mapping clinical ethics questions raised by new metagenomic techniques for diagnosing disease in clinical practice.
Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.
The Mastercard Foundation Scholars at Oxford's Africa Oxford Initiative receive full scholarships, rigorous education, leadership training, entrepreneurship support and networking, preparing them to lead Africa's and the world's future challenges and opportunities.
The Goding lab, working in collaboration with the University Rey Juan Carlos, have shown that fatty acid uptake activates an AXL-CAV1-\u03b2-catenin axis to drive melanoma invasiveness.
A landmark study involving researchers from NDM\u2019s Centre for Human Genetics has identified 69 previously unidentified genetic determinants of rare disease, including uncommon forms of epilepsy and schizophrenia.
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded \u00a35 million to a group of interdisciplinary researchers from NDM and other departments at the University, to develop new therapies for drug-resistant tuberculosis.
After more than a year of community engagement and preparation in 100 villages with over 12,000 inhabitants across the Chittagong Hill Tracts, a mass malaria vaccine (R21/Matrix M) and drug administration (DHA, piperaquine, and single low dose primaquine) study was launched on 15 February.
In the first study of this kind, NDM\u2019s Pandemic Sciences Institute and Oxford researchers partner with global colleagues to outline how artificial intelligence can transform infectious disease research and save more lives.
![\"\"](\"https://www.ndm.ox.ac.uk/news/up-to-ps16-5-million-awarded-to-global-consortium-for-infectious-disease-research/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n